Title : Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia.

Pub. Date : 2019 Jan

PMID : 30093398






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Dasatinib, a second-generation BCR-ABL1 tyrosine kinase inhibitor, is approved for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia, both as first-line therapy and after imatinib intolerance or resistance. Dasatinib ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens